Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
Is it finally time to sell Nvidia ahead of earnings?
Read More
Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?
By Zacks Investment ResearchStock MarketsMar 26, 2020 11:31PM ET
www.investing.com/analysis/editas-edit-up-01-since-last-earnings-report-can-it-continue-200519659
Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?
By Zacks Investment Research | Mar 26, 2020 11:31PM ET A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have added about 0.1% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Editas due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Editas Q4 Earnings & Sales Fall Shy of Estimates
Editas incurred a loss of 74 cents per share in the fourth quarter of 2019, much wider than the Zacks Consensus Estimate of 35 cents and also the year-ago loss of 52 cents.
Collaboration and other research and development revenues comprising the company’s total revenues came in at $12.3 million, up 101.6% year over year. However, the top line significantly missed the Zacks Consensus Estimate of $51 million.
Editas has no approved product in its portfolio at the moment. The company generates collaboration revenues and other research and development revenues. Its collaboration revenues increased in the fourth quarter owing to higher revenues recognized under its collaboration with Allergan (NYSE:AGN) and the amended collaboration agreement with Celgene (NASDAQ:CELG) (now part of Bristol-Myers).
Quarter in Detail
In the reported quarter, research and development expenses were $34.8 million, up 81.2% from the year-ago figure due to increased process and platform development costs.
General and administrative expenses also rose 28% to $16.9 million due to higher professional services costs.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month. The consensus estimate has shifted -17.8% due to these changes.
VGM Scores
Currently, Editas has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Editas Medicine, Inc. (EDIT): Free Stock Analysis Report
Original post
Related Articles
NVIDIA Earnings: Can Blackwell Chips Provide Tailwind?
By Dave Kovaleski - Feb 25, 2025
The markets have been sluggish this week as investors hope for a jolt later in the week when AI juggernaut NVIDIA Corporation (NASDAQ:NVDA) reports fourth quarter and year-end...
3 Dividend-Paying Stocks Bucking the Market’s Trend
By Ryan Hasson - Feb 25, 2025
On Friday, a wave of selling pressure swept across the US equity markets, leaving a trail of losses. The S&P 500 closed down 1.7%, the DOW slid 1.69%, and the NASDAQ tumbled a...
Palantir: Down 30% This Week, Is It Time to Flee the High-Flying...
By Alessandro Bergonzi - Feb 25, 2025
6
Palantir remains highly valued with a 460x P/E ratio and a 42.5x P/B ratio, far above its peers. The stock's beta of 2.81 signals high volatility, meaning sharp moves in both...
Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.